Patients with at least one grade 3 or 4 adverse effect classified by CTC criteria and NCI criteria according to randomization group
. | Fludarabine . | FC . | P . |
|---|---|---|---|
| No. patients | 173 | 173 | |
| CTC grades 3 and 4, % | |||
| All grades 3 and 4 toxicities | 54.0 | 72.6 | .001 |
| Myelotoxicity | 39.3 | 64.2 | .001 |
| Leukocytopenia | 26.0 | 55.5 | < .001 |
| Anemia | 11.6 | 8.1 | .28 |
| AIHA | 3.8 | 2.2 | .37 |
| Thrombocytopenia | 12.7 | 15.6 | .44 |
| Infection | 8.7 | 8.7 | >.999 |
| Gastrointestinal adverse effects | 1.7 | 5.8 | .05 |
| NCI grades 3 and 4, % | |||
| Anemia | 5.2 | 2.4 | .17 |
| Thrombocytopenia | 23.3 | 34.9 | .02 |
. | Fludarabine . | FC . | P . |
|---|---|---|---|
| No. patients | 173 | 173 | |
| CTC grades 3 and 4, % | |||
| All grades 3 and 4 toxicities | 54.0 | 72.6 | .001 |
| Myelotoxicity | 39.3 | 64.2 | .001 |
| Leukocytopenia | 26.0 | 55.5 | < .001 |
| Anemia | 11.6 | 8.1 | .28 |
| AIHA | 3.8 | 2.2 | .37 |
| Thrombocytopenia | 12.7 | 15.6 | .44 |
| Infection | 8.7 | 8.7 | >.999 |
| Gastrointestinal adverse effects | 1.7 | 5.8 | .05 |
| NCI grades 3 and 4, % | |||
| Anemia | 5.2 | 2.4 | .17 |
| Thrombocytopenia | 23.3 | 34.9 | .02 |